A Phase Ib/II Study of BEZ235 and Trastuzumab in Patients With HER2-positive Breast Cancer Who Failed Prior to Trastuzumab
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Locally Advance Breast Cancer (LABC)|Metastatic Breast Cancer (MBC)
Interventions: DRUG: BEZ235 + Trastuzumab Phase l/Phase ll)|DRUG: Lapatinib + Capecitabine (Phase II)
Sponsor: Novartis Pharmaceuticals